Dose-dependent effects of pharmaceutical treatments on bone matrix properties in ovariectomized rats.
Advanced glycation end-products
Alendronate
Osteocalcin
Osteopontin
Parathyroid hormone
Journal
Bone reports
ISSN: 2352-1872
Titre abrégé: Bone Rep
Pays: United States
ID NLM: 101646176
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
04
08
2021
revised:
23
09
2021
accepted:
28
09
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
As both anabolic and anti-catabolic osteoporosis drugs affect bone formation and resorption processes, they may contribute to bone's overall mechanical behavior by altering the quality of the bone matrix. We used an ovariectomized rat model and a novel fracture mechanics approach to investigate whether treatment with an anabolic (parathyroid hormone) or anti-catabolic (alendronate) osteoporosis drugs will alter the organic and mineral matrix components and consequently cortical bone fracture toughness. Ovariectomized (at 5 months age) rats were treated with either parathyroid hormone or alendronate at low and high doses for 6 months (age 6-12 months). Specifically, treatment groups included untreated ovariectomized controls (n = 9), high-dose alendronate (n = 10), low-dose alendronate (n = 9), high-dose parathyroid hormone (n = 10), and low-dose parathyroid hormone (n = 9). After euthanasia, cortical microbeams from the lateral quadrant were extracted, notched, and tested in 3-point bending to measure fracture toughness. Portions of the bone were used to measure changes in the 1) organic matrix through quantification of advanced glycation end-products (AGEs) and non-collagenous proteins, and 2) mineral matrix through assessment of mineral crystallinity. Compared to the ovariectomized group, rats treated with high doses of parathyroid hormone and alendronate had significantly increased cortical bone fracture toughness, which corresponded primarily to increased non-collagenous proteins while there was no change in AGEs. Additionally, low-dose PTH treatment increased matrix crystallinity and decreased AGE levels. In summary, ovariectomized rats treated with pharmaceutical drugs had increased non-collagenous matrix proteins and improved fracture toughness compared to controls. Further investigation is required for different doses and longer treatment periods.
Identifiants
pubmed: 34660852
doi: 10.1016/j.bonr.2021.101137
pii: S2352-1872(21)00394-6
pmc: PMC8503587
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101137Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
None of the authors have conflicts of interest to disclose.
Références
Scand J Clin Lab Invest. 2012 Feb;72(1):14-22
pubmed: 22085136
Injury. 2016 Jun;47 Suppl 2:S11-20
pubmed: 27338221
Bone. 2005 Dec;37(6):825-32
pubmed: 16140600
PLoS One. 2012;7(4):e35047
pubmed: 22514706
Calcif Tissue Int. 2012 Mar;90(3):165-73
pubmed: 22237954
Calcif Tissue Int. 2016 Oct;99(4):373-83
pubmed: 27240574
Curr Osteoporos Rep. 2012 Jun;10(2):169-77
pubmed: 22527725
JAMA. 1998 Dec 23-30;280(24):2077-82
pubmed: 9875874
J Bone Miner Res. 2019 Jul;34(7):1191-1206
pubmed: 30866111
J Orthop Res. 2020 May;38(5):972-983
pubmed: 31793028
Bone. 1995 Oct;17(4 Suppl):125S-133S
pubmed: 8579908
Sci Rep. 2015 Jun 01;5:10795
pubmed: 26027958
Cell Tissue Res. 1999 Aug;297(2):249-59
pubmed: 10470495
J Bone Miner Res. 2009 Feb;24(2):209-20
pubmed: 18847326
J Bone Miner Res. 1996 Apr;11(4):466-71
pubmed: 8992877
J Biomech. 2021 Feb 12;116:110243
pubmed: 33485148
J Exp Med. 1958 Feb 1;107(2):247-63
pubmed: 13491760
J Musculoskelet Neuronal Interact. 2002 Dec;2(6):538-43
pubmed: 15758388
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
Cell Signal. 2009 Aug;21(8):1245-54
pubmed: 19249350
J Mech Behav Biomed Mater. 2015 Dec;52:120-130
pubmed: 26530231
Bone. 2001 Feb;28(2):150-9
pubmed: 11182372
J Clin Endocrinol Metab. 2000 Feb;85(2):720-6
pubmed: 10690882
Sci Transl Med. 2009 Oct 7;1(1):1ra1
pubmed: 20368153
Bonekey Rep. 2012 Sep 19;1:182
pubmed: 24363926
Bone. 2001 Feb;28(2):195-201
pubmed: 11182378
J Clin Endocrinol Metab. 2000 Nov;85(11):4118-24
pubmed: 11095442
J Endocrinol. 2013 Oct 04;219(2):145-58
pubmed: 24096963
Nat Mater. 2005 Aug;4(8):612-6
pubmed: 16025123
J Mech Behav Biomed Mater. 2009 Aug;2(4):348-54
pubmed: 19627841
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473-5
pubmed: 1693772
Endocrinology. 2002 Sep;143(9):3230-42
pubmed: 12193534
Osteoporos Int. 2009 Jun;20(6):887-94
pubmed: 18850239
J Cell Biochem. 1991 Mar;45(3):292-302
pubmed: 2066381
J Clin Invest. 1993 May;91(5):2004-11
pubmed: 8486770
J Biomech. 2004 Jun;37(6):943-6
pubmed: 15111083
Nature. 1996 Aug 1;382(6590):448-52
pubmed: 8684484
Bone Joint Res. 2017 Jan;6(1):14-21
pubmed: 28062525
Osteoporos Int. 2011 Feb;22(2):577-85
pubmed: 20734029
Exp Ther Med. 2015 May;9(5):1967-1973
pubmed: 26136924
Osteoporos Int. 2017 Mar;28(3):1109-1119
pubmed: 27796444
Bone. 2007 Jun;40(6):1447-52
pubmed: 17045858
J Biol Chem. 2007 Feb 23;282(8):5691-703
pubmed: 17142454
Curr Osteoporos Rep. 2012 Jun;10(2):141-50
pubmed: 22535528
J Biomech. 1997 Aug;30(8):763-9
pubmed: 9239560
Am J Phys Anthropol. 2012 May;148(1):24-35
pubmed: 22331623
Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21
pubmed: 17043762
Toxicol Pathol. 2002 May-Jun;30(3):312-21
pubmed: 12051548
Exp Ther Med. 2018 Jan;15(1):182-190
pubmed: 29375681
Bone. 2002 Jul;31(1):1-7
pubmed: 12110404
Bone. 2006 Dec;39(6):1210-7
pubmed: 16962838
Osteoporos Int. 2013 Sep;24(9):2441-7
pubmed: 23471564
Endocrinology. 2017 Sep 1;158(9):2722-2740
pubmed: 28637206
Bone. 2011 Jul;49(1):56-65
pubmed: 20955825
Osteoporos Int. 2008 Mar;19(3):329-37
pubmed: 18094911
Calcif Tissue Int. 1993;53 Suppl 1:S127-32; discussion S132-3
pubmed: 8275366
Int J Clin Pract Suppl. 1999 Apr;101:3-8
pubmed: 12669734
Sci Rep. 2018 Jan 19;8(1):1191
pubmed: 29352125
J Clin Endocrinol Metab. 2000 Sep;85(9):3069-76
pubmed: 10999788
J Bone Miner Metab. 2007;25(6):345-53
pubmed: 17968486
Bone. 2006 Nov;39(5):1053-1058
pubmed: 16807159
Osteoporos Int. 2008 Sep;19(9):1343-54
pubmed: 18373056
Am J Med. 1995 Aug;99(2):144-52
pubmed: 7625419
Calcif Tissue Int. 2014 Nov;95(5):446-56
pubmed: 25190190
Bone. 2012 Mar;50(3):596-604
pubmed: 22226688
Bone. 2010 Oct;47(4):766-72
pubmed: 20633708
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19178-83
pubmed: 23129653
J Clin Invest. 1999 Aug;104(4):439-46
pubmed: 10449436
J Cell Biol. 1994 Nov;127(4):1149-58
pubmed: 7962073
J Int Med Res. 2009 Mar-Apr;37(2):407-16
pubmed: 19383235
Bone. 2008 Apr;42(4):695-701
pubmed: 18295560
Ann N Y Acad Sci. 2017 Dec;1409(1):79-84
pubmed: 29044594
Bone. 2008 Jan;42(1):139-49
pubmed: 17974517
J Bone Miner Res. 2007 Jul;22(7):1037-45
pubmed: 17402847
Bone. 2012 Dec;51(6):981-9
pubmed: 22975110
Bone. 1999 Sep;25(3):301-9
pubmed: 10495134
J Biomech. 2018 Oct 26;80:45-52
pubmed: 30205977
Bone. 1998 Sep;23(3):187-96
pubmed: 9737340
Mol Cell Proteomics. 2011 Sep;10(9):M110.006718
pubmed: 21606484
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):285-91
pubmed: 15716833
Nat Mater. 2003 Mar;2(3):164-8
pubmed: 12612673
Osteoporos Int. 2011 Aug;22(8):2373-83
pubmed: 20959962
J Musculoskelet Neuronal Interact. 2005 Oct-Dec;5(4):316
pubmed: 16340119
J Bone Miner Res. 2007 Feb;22(2):286-97
pubmed: 17087627
J Bone Miner Res. 2012 Mar;27(3):702-12
pubmed: 22161803
J Orthop Res. 2007 May;25(5):646-55
pubmed: 17266142
Bone. 2018 Sep;114:32-39
pubmed: 29857063
Ann N Y Acad Sci. 2017 Dec;1410(1):93-106
pubmed: 29265417
Bone. 2010 Jun;46(6):1564-73
pubmed: 20171304
Bone. 1999 Jul;25(1):97-106
pubmed: 10423031
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Feb 15;879(5-6):379-85
pubmed: 21242109
Bone. 1996 Sep;19(3):281-90
pubmed: 8873969
Bone. 2007 Apr;40(4):1144-51
pubmed: 17257914
Osteoporos Int. 2000;11(1):83-91
pubmed: 10663363
J Intern Med. 2017 Dec;282(6):546-559
pubmed: 28857352
Bone. 1998 Mar;22(3):233-9
pubmed: 9580147
Bone. 2008 Nov;43(5):798-812
pubmed: 18647665